A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania

Vaccine

Volumn 30, Issue 36, 2012, Pages 5363-5367

  Remes, Pieter ^a,b   Selestine, Veronica ^a   Changalucha, John ^c   Ross, David A ^d   Wight, Daniel ^b   de Sanjosé, Silvia ^e   Kapiga, Saidi ^a   Hayes, Richard J ^d   Watson Jones, Deborah ^a,d  

^a National Institute for Medical Research   (Tanzania)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Acceptability; Barriers; Human papillomavirus; Schools; Tanzania; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; ATTITUDE TO HEALTH; CHILD; CLERGY; FEMALE; HEALTH PERSONNEL ATTITUDE; HEALTH SERVICE; HUMAN; INFORMED CONSENT; KNOWLEDGE; MALE; PARENTAL ATTITUDE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; SCHOOL CHILD; SEMI STRUCTURED INTERVIEW; STUDENT ATTITUDE; TANZANIA; TEACHER; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADULT; FACULTY; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; QUALITATIVE RESEARCH; TANZANIA; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84864004878     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.025     Document Type: Article

References (42)

1. International Agency for Research on Cancer. Estimated cervical cancer mortality worldwide in 2008. Available at [last accessed: June 2011]. http://globocan.iarc.fr/factsheets/cancers/cervix.asp.
2. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers in Tanzania. Summary Report 2010. Available at [last accessed: January 2011]. http://www.who.int/hpvcentre.
3. Harper D.M., Franco E.L., Wheeler C., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
4. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 viruslike particle vaccine through 5 years follow-up. Br J Cancer 2006, 6:1459-1466.
5. De Carvalho N., Teixeira J., Roteli-Martins C.M., Naud P., De Borba P., Zahaf T., et al. Sustained efficacy and immunogenicity of the HPV 16/18 ASO4-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28:6247-6255.
6. World Health Organization Human papillomavirus vaccines WHO position paper. Wkly Epidemiol Rec 2009, 15(84):117-132.
7. Stokley S., Cohn A., Jain N., McCauley M.M. Compliance with recommendations and opportunities for vaccination at ages 11-12 years: evaluation of the 2009 National Immunization Survey-Teen. Arch Pediatr Adolesc Med 2011, 165(9):813-818.
8. Department of Health & Health Protection Agency. Annual HPV vaccine coverage in England in 2009/2010. Available at [last accessed: September 2011]. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_123826.pdf.
9. Dorell C., Stokley S., Yankey D., Liang J., Markowitz L. National and state vaccinattion coverage among adolescents aged 13 through 17 years, United States, 2010. Morb Mortal Wkly Rep 2011, 60(33):1117-1123.
10. European Cervical Cancer Association. HPV vaccination across Europe. Available at [last accessed: September 2011]. http://www.ecca.info/fileadmin/user_upload/HPV_Vaccination/ECCA_HPV_Vaccination_April_2009.pdf.
11. PATH. Report of an African Regional Meeting on Cervical Cancer. Improved cervical cancer prevention: planning now for a better future, September 14-15, 2010, Kampala, Uganda. Seattle: Path, 2010. Available at [last accessed: September 2011]. http://www.rho.org/files./PATH_Africa_cxca_conf_report_2010.pdf.
12. Watson-Jones D., Baisley K., Ponsiano R., Remes P., Changalucha J., Kapiga S., et al. HPV vaccination in Tanzanian schoolgirls: cluster-randomised trial comparing two vaccine delivery strategies. J Infect Dis 2012, 10.1093/infdis/jis407.
13. Rwanda, Merck and QIAGEN launch Africa's first comprehensive cervical cancer prevention program incorporating both HPV vaccination and HPV testing. Available at [last accessed: July 2011]. http://www.merck.com/newsroom/news-release-archive/vaccine-news/2011_0425.html.
14. Musoni E. Cervical cancer vaccination registers 97% coverage. The New Times, June 20, 2011. Available at [last accessed: May 2012]. http://www.newtimes.co.rw/news/index.php%3Fi=14662%26a=42404.
15. Davis K., Dickman E.D., Ferris D., Dias J.K. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis 2004, 8(3):188-194.
16. Olshen E., Woods E.R., Bryn Austin S.B., Luskin M., Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health 2005, 37(3):248-251.
17. Charo R.A. Politics, parents, and prophylaxis - mandating HPV vaccination in the United States. N Engl J Med 2007, 356(19):1905-1908.
18. Harries J., Moodley J., Barone M.A., Mall S., Sinanovic E. Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine 2009, 27(1):38-44.
19. Katahoire R.A., Jitta J., Kivumbi G., Murokora D., Arube W.J., Siu G., et al. An assessment of the readiness for introduction of the HPV vaccine in Uganda. Afr J Reprod Health 2010, 12(3):159-172.
20. PATH. Child health and development centre (CHDC), and the Uganda national expanded program on immunization (UNEPI). HPV vaccination in africa: lessons learned from a pilot program in Uganda. Seattle: PATH; 2011.
21. Bartolini R.M., Drake J.K., Creed-Kanashiro H.M., Díaz-Otoya M.M., Mosqueira-Lovón N.R., Penny M.E., et al. Formative research to shape HPV vaccine introduction strategies in Peru. Salud Pública Méx 2010, 52(3):226-233.
22. Jacob M., Mawar N., Menezes L., Kaipilyawar S., Gandhi S., Khan I., et al. Assessing the environment for introduction of human papillomavirus vaccine in India. Open Vaccine J 2010, 3:96-107.
23. Plummer M., Wight D. Young people's lives and sexual relationships in rural Africa: findings from a large qualitative study in Tanzania 2011, Lexington Books, Lanham.
24. Zaba B., Isingo R., Wringe A., Marston M., Slaymaker E., Urassa M. Influence of timing of sexual debut and first marriage on sexual behaviour in later life: findings from four survey rounds in the Kisesa cohort in northern Tanzania. Sex Transm Infect 2009, 85(Suppl. 1):i20-i26.
25. National Bureau of Statistics (NBS) [Tanzania] and ICF Macro. Tanzania Demographic and Health Survey 2010. Dar es Salaam: NBS and ICF Macro; 2011.
26. Integrated Regional Information Networks (IRIN). Tanzania: vaccination campaign treats millions of children. Dar Es Salaam, 2 September 2008. Available at [last accessed: April 2012]. http://www.irinnews.org/Report.aspx%3FReportId=80123.
27. Milstien J.P., Griffin D., Lee J-W. Damage to immunisation programmes from misinformation on contraceptive vaccines. Reprod Health Matters 1995, 3(6):24-28.
28. Clements J., Drake C. Combating anti-vaccination rumours: lessons learned from case studies in East Africa 2002, UNICEF Eastern and Southern Africa Regional Office, Nairobi.
29. Bingham A., Drake J., LaMontagne S. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med 2009, 163(5):455.
30. Katahoire R.A., Jitta J., Arube-Wani J., Kivumbi G., Murokora D., Siu G., et al. Formative research report: an assessment of the readiness for introduction of a cervical cancer vaccine in Uganda 2008, Child Health and Development Center, Makerere University, Kampala.
31. Becker-Dreps S., Otieno W.A., Brewer N., Agot K., Smith J.S. HPV vaccine acceptability among Kenyan women. Vaccine 2010, 28(31):4864-4867.
32. DiAngi Y.T., Panozzo C.A., Ramogola-Masire D., Steenhoff A.P., Brewer N. A cross-sectional study of HPV vaccine acceptability in Gaborone, Botswana. PLoS ONE 2011, 6(10):e25481.
33. Coleman M.A., Levison J., Sangi-Haghpeykar H. HPV vaccine acceptability in Ghana, West Africa. Vaccine 2011, 29:3945-3950.
34. Francis S.A., Nelson J., Liverpool J., Soogund S., Mofammered N., Thorpe R.J. Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic attendees in Johannesburg: South Africa. Vaccine 2010, 28(50):8026-8032.
35. Kaler A. Health interventions and the persistence of rumour: the circulation of sterility stories in African public health campaigns. Soc Sci Med 2009, 68(9):1711-1719.
36. Geissler P.W., Pool R. Editorial: popular concerns about medical research projects in sub-Saharan Africa - a critical voice in debates about medical research ethics. Trop Med Int Health 2006, 11(7):975-982.
37. Kristina T., Naushin N., Elit L., Roy K. Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: a systematic review from 2001 to 2011. Article ID 921236. Obstet Gynecol Int 2012, 10.1155/2012/921236.
38. Constantine N.A., Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 2007, 40:108-115.
39. Dempsey A.F., Zimet G.D., Davis R.L., Koutksy L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 2006, 117(5):1486-1493.
40. Brewer N.T., Fazekas K.I. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007, 45(2-3):107-114.
41. Reiter P., Brewer N., Gottlieb S.L., McRee A-L., Smith J.S. Parents' health beliefs and HPV vaccination of their adolescent daughters. Soc Sci Med 2009, 69(3):475-480.
42. Global Alliance for Vaccines and Immunisation. GAVI welcomes lower prices for life-saving vaccines. Available at [last accessed: June 2011]. http://www.gavialliance.org/media_centre/press_releases/vaccine_prices.php.